Teva Pharmaceutical Industries vs United Therapeutics Corporation — Valuation Comparison 2026
Access all valuation models for TEVA vs UTHR — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.
Access Full Analysis — From $27/mo →UTHR scores higher with a 10.0/10 quality rating vs TEVA's 6.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
Comparing Teva Pharmaceutical Industries (TEVA) and United Therapeutics Corporation (UTHR) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.
TEVA currently trades at $34.52 with a QOC of 6.7/10, while UTHR trades at $562.09 with a QOC of 10.0/10.
Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).